Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06951867 · ClinicalTrials.gov registry record

Tezspire Cardiac Events PASS

A clinical trial of Cardiovascular Events and MACE, sponsored by AstraZeneca.

Recruiting
Registry status
16,640
Enrollment target
4
Study locations

NCT06951867: Recruiting study of Cardiovascular Events and MACE, sponsored by AstraZeneca.

NCT06951867 is a study of Cardiovascular Events and MACE that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 16,640 participants. The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06951867, a study of Cardiovascular Events and MACE, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
16,640 participants
Enrollment target
4
Study locations

Study Summary

The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.

Primary Outcome

The primary outcome of interest is the composite outcome MACE, consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death.

Interventions

  • DRUG Tezepelumab

Study Locations (4)

Other

  • Danish registries (access/analysis) - Copenhagen
  • French National Health Data System (SNDS) - Paris
  • Team Gesundheit GKV Claims data (SHI) - Berlin

Delaware

  • Healthcare Integrated Research Database (HIRD) - Wilmington

Trial Details

FieldValue
Enrollment Target 16,640 participants
Start Date 2025-09-15
Est. Completion 2029-05-31
AstraZeneca

1,285 total trials

What NCT06951867 shows while recruiting

NCT06951867 is an observational study that tracks outcomes without assigning an intervention. Its 16,640 participants enrollment target places it among the larger protocols in the corpus.

The record links to 2 conditions, with Cardiovascular Events appearing as the primary indexed condition, and to 1 intervention - of which Tezepelumab is the first listed.

NCT06951867 reports a single indexed study location in Other, Delaware.

Frequently Asked Questions

What is clinical trial NCT06951867 about?

NCT06951867 is a clinical study titled "Tezspire Cardiac Events PASS". The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.

What is the current status of trial NCT06951867?

This trial is currently recruiting. The enrollment target is 16,640 participants. The study started on 2025-09-15. Estimated completion is 2029-05-31.

What conditions does trial NCT06951867 study?

This clinical trial studies the following conditions: Cardiovascular Events, MACE.

What interventions are being tested in trial NCT06951867?

The interventions under investigation include: Tezepelumab (DRUG).

Who is sponsoring clinical trial NCT06951867?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06951867 being conducted?

This trial has 4 study locations across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Events

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06948838 · 16,895 participants · NA

    Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment

  • NCT06479447 · 17,000 participants · NA

    Patient Outcome Reporting for Timely Assessments of Life With Post-Traumatic Stress Disorder

  • NCT06245187 · 17,198 participants

    Get With the Guidelines Atrial Fibrillation Registry

  • NCT01737528 · 16,000 participants

    STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06951867, the US trial registry maintained by the National Library of Medicine. NCT06951867 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.